news
The novel peripheral serotonin antagonist, based on Parkinson’s drug pimavanserin,…
2 June 2020 | By Hannah Balfour (Drug Target Review)
The novel peripheral serotonin antagonist, based on Parkinson’s drug pimavanserin, increased glucose tolerance and lean body mass in a murine model of non-alcoholic fatty liver disease (NAFLD).